Industry context
VYNE Therapeutics Inc [VYNE]
Última actualización 25 Jun 2026 @ 16:00 (Exchange is closed)
Último: $0.652
0.17%
0.00 (↑)
GaG Algo Score™
v1.0
Corto
0.00 (↑)
Medio
1.32 (↑)
Largo
1.67 (↑)
Línea
Datos pivot
Estadísticas pivot
No hay suficientes datos pivot para estadísticas.
Predicción del próximo pivot Último: $0.65
No se puede generar una predicción con los datos disponibles.
Slight gain for VYNE Therapeutics Inc.
VYNE Therapeutics Inc (VYNE) stock price edged up slightly on Thursday after the stock rose $0.00110 (0.17%) from the previous session on normal volume. The stock held up slightly better than the falling NASDAQ (-0.46% down). With 107 610 shares traded, volume yesterday reached $70 129. This was 54 934 shares less than the prior day. Compared to the 10-day average of 133 229 shares, volume was less than the average.
VYNE Therapeutics Inc signals
There is no conclusive signals given from RSI. The price is below the short-term average but above the long-term average, with a bullish crossover; this represents a pullback within a broader up-trend. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (6.7%), medium- (6.7%), and long-term (6.7%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
VYNE Therapeutics Inc Support & Resistance Levels
The stock is trading above the closest support level at $0.600. approximately $0.0517 (7.93%) away. This suggests it is currently acting as a floor, approaching it.The sup dis das support s10.6 -
VYNE Therapeutics Inc Evaluation
- Corto puntuación: 0.00
- Medio puntuación: 1.32
- Largo puntuación: 1.67
Ownership flow
GetAGraph InsiderPower
Transactions
67
Buy power
4.35M
Sell power
293.5K
Reliability
100/100
Buy / sell
14.82
Hist. corr.
0.10
Latest signal
Buy 2026-06-25
Officer 37
Executive 15
Director 15
2026-05-29
Domzalski David Executive
Buy 30 791
2026-03-31
Zeronda Tyler Officer
Sell 4 007
2026-03-31
Stuart Iain Officer
Sell 2 876
2026-03-31
Harsch Mutya Officer
Sell 4 007
2026-03-31
Domzalski David Executive
Sell 14 232
2026-03-31
Zeronda Tyler Officer
Other 4 007
Relationship map
Correlation snapshot
Positioning pressure
Short interest pressure
Short interest
0.72%
Of outstanding shares
Short float
0.88%
Of tradable float
Days to cover
1.000
Short interest divided by average volume
Squeeze probability
1.90%
-1.54% change
Short positioning does not currently stand out as a dominant risk factor.
Updated 2026-05-29Earnings quality
Earnings history
Reported quarters
10
EPS beats
6
EPS misses
4
Avg. surprise
-4.65%
VYNE Therapeutics Inc Estimated Earnings vs Actual Earnings
Actual EPS
Estimated EPS
Miss
Q2/2023
Miss
Q3/2023
Beat
Q4/2023
Beat
Q1/2024
Miss
Q2/2024
Miss
Q3/2024
Beat
Q4/2024
Beat
Q1/2025
Waiting
Q2/2025
Waiting
Q3/2025
VYNE Therapeutics Inc Earnings History
| Date | Period | EPS estimate | Actual EPS | EPS surprise | Revenue estimate | Revenue actual | Revenue surprise |
|---|---|---|---|---|---|---|---|
| 2025-11-05 | Q3/2025 | - | - | Waiting | - | - | Waiting |
| 2025-08-13 | Q2/2025 | $-0.290 | - | Waiting | 150 000 | - | Waiting |
| 2025-05-08 | Q1/2025 | $-0.290 | $-0.200 | Beat 31.03% | 50 000 | 202 000 | Beat 304.00% |
| 2025-03-06 | Q4/2024 | $-0.310 | $-0.280 | Beat 9.68% | 100 000 | 84 000 | Miss -16.00% |
| 2024-11-07 | Q3/2024 | $-0.240 | $-0.290 | Miss -20.83% | 140 000 | 121 000 | Miss -13.57% |
| 2024-08-14 | Q2/2024 | $-0.190 | $-0.220 | Miss -15.79% | 110 000 | 198 000 | Beat 80.00% |
| 2024-05-09 | Q1/2024 | $-0.240 | $-0.150 | Beat 37.50% | 110 000 | 98 000 | Miss -10.91% |
| 2024-02-29 | Q4/2023 | $-0.500 | $-0.200 | Beat 60.00% | 150 000 | 76 000 | Miss -49.33% |
| 2023-11-13 | Q3/2023 | $-0.760 | $-1.850 | Miss -143.42% | 150 000 | 114 000 | Miss -24.00% |
| 2023-08-14 | Q2/2023 | $-1.990 | $-3.08 | Miss -54.77% | 100 000 | 135 000 | Beat 35.00% |
| 2023-05-11 | Q1/2023 | $-2.50 | $-1.740 | Beat 30.40% | - | 99 000 | Waiting |
| 2023-03-09 | Q4/2022 | $-3.24 | $-2.60 | Beat 19.75% | 60 000 | 6 000 | Miss -90.00% |
Analyst view
Analyst targets
Consensus
$5.75
Median
$5.75
Low
$5.75
High
$5.75
Recent target updates
News flow
Latest company news
Market coverage
defenseworld.net Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Decreases By 35.7% Apr 15, 2026 defenseworld.net Contrasting Vivani Medical (NASDAQ:VANI) & VYNE Therapeutics (NASDAQ:VYNE) Mar 15, 2026 defenseworld.net VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Down 61.3% in February Mar 11, 2026 prnewswire.com Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders Dec 18, 2025Company releases
Company context
Company profile
Bolsa:
NASDAQ
Sector:
Healthcare
Industria:
Biotechnology
Currency
USD
VYNE Therapeutics Inc is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immunemediated inflammatory conditions Its development portfolio features FCD105 a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderatetosevere acne vulgaris Another candidate in its pipeline is FMX114 a combination treatment incorporating tofacitinib which is currently in earlystage clinical assessment referred to as a Phase IIa preclinical trial for addressing mildtomoderate atopic dermatitis Additionally the company is progressing VYN201 a bromodomain and extraterminal BET inhibitor designed to target a range of immunoinflammatory disorders notably those affecting the skin A further asset is VYN202 which comprises BET inhibitor compounds engineered for selective action on bromodomain 2 Established in 2003 the firm was formerly recognized as Menlo Therapeutics Inc before officially changing its corporate identity to VYNE Therapeutics Inc in September 2020 The companys principal operations are based in Bridgewater New Jersey
Navigation